SMI 3Fourteen Full-Cycle Trend ETF (FCTE)
Live price chart, market sentiment, and community perspectives for SMI 3Fourteen Full-Cycle Trend ETF (NASDAQ: FCTE).
Live price chart, market sentiment, and community perspectives for SMI 3Fourteen Full-Cycle Trend ETF (NASDAQ: FCTE).
Looking at the portfolio metrics on our desk, FCTE's 354% annual turnover is an immediate red flag for taxable accounts. Generating that much churn with a 1-year return of -1.23% means clients are paying a 0.85% expense ratio plus heavy transaction and tax friction for below-average performance relative to large blend peers.
Sentiment across the trading community feels decidedly cautious. Danelfin's AI score places it at a 2/10 'Strong Sell' due to a -3.63% probability advantage against the wider ETF universe over the next quarter, which matches Morningstar's quantitatively derived Negative rating on its process pillar.
When evaluating the rules-based trend-and-quality strategy for our risk models, I note it holds only 20 SandP 500 stocks with a forward P/E around 23.7x. While the sector tilt toward Technology (~29%), Industrials (~26%), and Healthcare (~21%) targets defensive quality, the lack of a multi-year track record since its July 2024 launch makes historical stress testing impossible.
On the options and technical desk, we saw the 10-day RSI oscillator finally leave overbought territory back in mid-August 2026. Coupled with a 104.8% surge in short interest during June—even if total short interest remains a modest 0.1% of shares—momentum traders are actively looking at put option spreads as the trend risks shifting downward.
From a quantitative risk management perspective, FCTE lands in an unfavorable quadrant: it takes below-average risk with a beta of 0.75, but it fails to deliver proportional returns. With Sharpe and Sortino ratios hovering near zero or negative, investors are simply not being compensated for holding a high-turnover trend fund in a normalized yield curve environment.
Explore plasma cleansing, somatic organ swaps, and BCI.